SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

Search

Imerys SA.

Închisă

SectorSănătate

21.12 0.67

Rezumat

Modificarea prețului

24h

Curent

Minim

19.9

Maxim

21.38

Indicatori cheie

By Trading Economics

Venit

-550M

-479M

Vânzări

-130M

1.6B

Randament dividend

3.49

Marjă de profit

-29.457

Angajați

14,878

EBITDA

-310M

-43M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+55.71% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.49%

2.47%

Următoarele câștiguri

27 apr. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-358M

1.8B

Deschiderea anterioară

20.45

Închiderea anterioară

21.12

Sentimentul știrilor

By Acuity

33%

67%

84 / 350 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Imerys SA. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 mar. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar. 2026, 22:55 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar. 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar. 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar. 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Global Equities Roundup: Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar. 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar. 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar. 2026, 22:18 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar. 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar. 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar. 2026, 21:10 UTC

Evenimente importante

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk
Câștiguri
Evenimente importante

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Imerys SA. Așteptări

Obiectiv de preț

By TipRanks

55.71% sus

Prognoză pe 12 luni

Medie 32.2 EUR  55.71%

Maxim 32.2 EUR

Minim 32.2 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruImerys SA. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

29.06 / 30.24Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

84 / 350 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Imerys SA.

Imerys S.A. provides mineral-based specialty solutions for various industries worldwide. The company provides additives for paints, coatings, adhesives, caulks, sealants, and rubber; minerals for technical ceramics and traditional ceramics; functional additives for plastics and thermoset; high-performance binders for dry mix mortars and floor screeds; fillers and coatings for paper, board, and packaging applications; filtration agents for liquids and blood plasma; pharmaceutical diluents, coloring agents, processing aids, glidants, and lubricants for tablet production; engineered minerals for cosmetic industry; food additives to preserve flavor; coating agents to improve fertilizer fow; mineral-based cat litters; alumina for high-performance abrasives and graphite in brake pads; and carbon black for conductivity in onboard data systems. The company also offers minerals used to produce high purity silicon metal for electronics and solar panels; graphite and carbon-based solutions for industrial applications; mineral solutions for batteries and energy storage; refractory minerals and solutions for high-temperature processes; and alumina and zirconia for abrasives. It serves construction and infrastructure, consumer and health care, automotive and transportation, energy and electronics, and industry and equipment industries. The company was incorporated in 1880 and is headquartered in Paris, France. The company is a subsidiary of Belgian Securities BV.
help-icon Live chat